Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented robust financial performance with a 38% revenue increase and a $5.1 million net income. The company has a strong cash position with no debt and has initiated a $10 million share buyback program. Despite some regulatory uncertainties, the strong growth in e-commerce and ingredient business, coupled with strategic market expansion plans, and positive product reception indicate a strong positive sentiment. The lack of market cap data suggests potential for a strong stock price reaction.
Key Financial Performance
Revenue $30.5 million, a 38% increase year-over-year.
Net Income $5.1 million, year-over-year change not specified.
Cash from Operations $7.9 million, year-over-year change not specified.
Cash Balance $55.6 million, no debt.
E-commerce Net Sales $16.8 million, a 31% increase year-over-year.
Food Grade and Pharmaceutical Grade Niagen Ingredient Business $8 million, a 95% increase year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue Growth: In the first quarter, Niagen Bioscience delivered $30.5 million in revenue, a 38% year-over-year increase.
E-commerce Sales: E-commerce continued to be a main driver of top-line growth with net sales of $16.8 million, a 31% increase year-over-year.
Niagen Ingredient Business: The food grade and pharmaceutical grade Niagen ingredient business grew to $8 million, a 95% increase year-over-year.
Cash Generation: Generated $7.9 million of cash from operations.
Cash Position: Ended the quarter with $55.6 million in cash and no debt.
Rebranding: This is the first investor call as Niagen Bioscience, formerly known as ChromaDex.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
Regulatory risks: The timing of future regulatory filings and the results of clinical trials are uncertain, which could impact business development opportunities.
Market conditions: Global market and economic conditions may affect the company's operations, financial conditions, and cash flows.
Competitive pressures: The company faces competitive pressures in the market, which could impact its growth and revenue.
Financial performance: The company’s financial results are subject to fluctuations that could affect investor interest and business prospects.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: In Q1 2025, Niagen Bioscience reported $30.5 million in revenue, a 38% year-over-year increase.
Net Income: The company achieved a net income of $5.1 million in Q1 2025.
Cash from Operations: Generated $7.9 million of cash from operations in Q1 2025.
E-commerce Growth: E-commerce sales reached $16.8 million, a 31% increase year-over-year.
Ingredient Business Growth: Food grade and pharmaceutical grade Niagen ingredient business grew to $8 million, a 95% increase year-over-year.
Cash Position: Ended Q1 2025 with $55.6 million in cash and no debt.
Future Outlook: The company anticipates continued growth in e-commerce and ingredient sales, with plans for expansion into new markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: The company has initiated a share buyback program, allocating $10 million for the repurchase of shares.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What do you see as emerging tailwinds for adoption of the Niagen IV product lineup?
A:We continue to see dramatic interest from clinics and physicians in offering Niagen IV. Events with influencers have shown that Niagen IV elevates NAD levels much higher without uncomfortable side effects and takes minutes instead of hours.
Q:Are there new promotional strategies to push more volume via the e-commerce channel?
A:We have seen over 30% growth in e-commerce. We are focused on profitability and efficiency, and while we may engage with influencers, we will not pursue aggressive cost-inefficient deals.
Q:How many clinics do you think are a good fit for Niagen Plus?
A:We hope to be in 1,000 clinics by the end of the year, with an addressable market of 2,000 to 3,000 clinics.
Q:What are the ordering patterns from initial clinics?
A:We have some anecdotal data showing benefits like improved sleep and a 'Niagen Glow', but we are still conducting studies to gather more concrete data.
Q:Can you update us on the status of the injectable side of Niagen Plus?
A:It is being offered in many clinics, and we are developing an at-home version expected to be available by the end of the year.
Q:What is the status of discussions with the FDA regarding ataxia-telangiectasia?
A:We are having active discussions with the FDA and have submitted a pre-IND. The process is progressing, but we have not engaged with third-party partners yet.
Q:How are the various Tru Niagen formulations performing?
A:They are selling but do not yet have a meaningful impact on overall sales. We expect to invest more in marketing for these products.
Q:Will the at-home injectable be available online?
A:Yes, consumers will be able to order them online, potentially through telehealth companies.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific timeline for the at-home injectable version of Niagen Plus, stating it could be available by the fourth quarter but did not provide a definitive date. Additionally, there was a lack of clarity on the exact nature of the ongoing discussions with the FDA regarding ataxia-telangiectasia, as well as the specifics of the marketing strategies for e-commerce.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Affairs Dr
Bioscience Conference
Bioscience Form
Bioscience activity
Bioscience news
Bioscience website
Biosciences Chief
Biosciences Inc
Conference today
Dr QA
Finance Mr
Inc Conference
Mr afternoon
Niagen Bioscience
Niagen Biosciences
Niagen product
Officer Chief
Officer Vice
President Finance
QA Today
Transcript Ladies
Wesley Vice
afternoon Niagen
conference Wesley
factor Niagen
gentleman Niagen
listen mode
participant listen
sale Niagen
section Niagen
statement research
today Niagen
website pleasure
NAGE Transcript
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call reveals strong financial performance, with 12% revenue growth and improved margins. The company projects continued growth through new product launches and market expansions. Despite regulatory and market expansion risks, the optimistic guidance and strategic initiatives, such as increased R&D and capital expenditures, suggest positive sentiment. The absence of negative sentiment in the Q&A further supports this view. Overall, the positive financial results and forward-looking strategies indicate a likely positive stock price movement in the short term.
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong financial performance with a 30% YoY revenue growth and improved net income and gross margin. The company has no debt and substantial cash reserves, indicating financial stability. Positive factors include a new partnership expanding distribution, a conservative yet confident guidance, and a $10 million share buyback plan. Although there are some uncertainties, such as legal issues with the FDA, the overall sentiment is positive, driven by strong financials and strategic growth initiatives.
Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call shows strong financial performance, with significant revenue growth and improved net income. The strategic partnership and strong balance sheet are positive indicators. Despite some uncertainties in the Q&A, such as the new partnership's feedback and rollout timelines, the overall sentiment is positive due to the optimistic outlook on margins and potential market expansion. The absence of debt and increased cash flow bolster the positive sentiment. Without market cap data, a precise prediction is challenging, but overall indicators suggest a positive impact on the stock price.
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call presented robust financial performance with a 38% revenue increase and a $5.1 million net income. The company has a strong cash position with no debt and has initiated a $10 million share buyback program. Despite some regulatory uncertainties, the strong growth in e-commerce and ingredient business, coupled with strategic market expansion plans, and positive product reception indicate a strong positive sentiment. The lack of market cap data suggests potential for a strong stock price reaction.
NAGE Slides
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
